Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded at Zacks Research

Zacks Research upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a hold rating to a strong-buy rating in a report issued on Thursday morning,Zacks.com reports.

Several other equities analysts also recently issued reports on IRWD. Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Wells Fargo & Company boosted their target price on shares of Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.34.

Ironwood Pharmaceuticals Trading Up 26.7%

Shares of IRWD opened at $4.27 on Thursday. The firm has a market cap of $694.64 million, a PE ratio of 26.69 and a beta of 0.18. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $5.78. The stock has a fifty day moving average price of $3.06 and a 200-day moving average price of $1.79.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative return on equity of 15.17% and a net margin of 8.70%.The company had revenue of $122.06 million for the quarter, compared to analyst estimates of $74.22 million. As a group, research analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of IRWD. OVERSEA CHINESE BANKING Corp Ltd purchased a new position in Ironwood Pharmaceuticals during the 2nd quarter worth approximately $25,000. Integrated Wealth Concepts LLC increased its stake in shares of Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,406 shares during the period. R Squared Ltd raised its holdings in shares of Ironwood Pharmaceuticals by 286.5% during the second quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 28,735 shares during the last quarter. Focus Partners Advisor Solutions LLC raised its holdings in shares of Ironwood Pharmaceuticals by 284.6% during the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 29,409 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new position in Ironwood Pharmaceuticals during the second quarter valued at $32,000.

Key Stores Impacting Ironwood Pharmaceuticals

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Company-issued FY‑2026 guidance projects revenue of $450–$475M, well above street estimates (~$319.5M), and forecasts higher adjusted EBITDA — the main catalyst for today’s rally. Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
• Positive Sentiment: Analyses note LINZESS net pricing and mix are turning into a durable growth lever, supporting the upgraded multi‑year revenue outlook and reducing downside risk relative to prior years. Ironwood Finds a New Floor as LINZESS Net Pricing Turns Into a Growth Lever
• Positive Sentiment: News and trade flow show heavy retail/institutional interest: unusually large options activity with calls rising ~582% vs. norm and very high share volume — signals bullish positioning and short-covering potential.
• Positive Sentiment: Recent quarterly results showed better-than-expected EPS and revenue growth (Q3 revenue up ~33% YoY), reinforcing management’s ability to convert LINZESS performance into profit and cash flow. Why Ironwood Pharmaceuticals, Inc.’s (IRWD) Stock Is Up 60.00%
• Neutral Sentiment: Media coverage (Benzinga, others) highlights the rally and guidance but adds limited new forward modeling — useful for momentum but not a substitute for detailed analyst estimates. Ironwood Pharma Stock Rallies On Strong 2026 Outlook
• Negative Sentiment: Insider activity shows multiple open‑market insider sales (no purchases reported in recent months), which some investors view as a cautionary signal on near‑term insider conviction. Ironwood Pharmaceuticals Stock (IRWD) Opinions on 2026 Financial Guidance
• Negative Sentiment: Social‑media and forum commentary includes skepticism about sustainability given biotech sector volatility; some traders warn the move could be momentum-driven and subject to pullback. Ironwood Pharmaceuticals Stock (IRWD) Opinions on 2026 Financial Guidance

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.